Lymphangioleiomyomatosis Clinical Trial
Official title:
Biomarkers for Tuberous Sclerosis Complex: An International Multicenter Observational Longitudinal Protocol
International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s
Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder characterized by the growth of numerous tumors in different body parts related to dysregulation of the mechanistic target of rapamycin (mTOR) pathway. The overall incidence of TSC is estimated to be as high as 1 in 6000 to 10,000 live birth.The main aspects of TSC that influence the quality of life are associated with the brain: seizures, evelopmental delay, intellectual disability, and autism. However, the incidence and severity of the various aspects of TSC can vary widely. TSC is generally caused by pathogenic variants in the tumor suppressor genes: TSC1 and TSC2. Confirmation of a clinical diagnosis of tuberous sclerosis is performed via TSC1 and TSC2 sequencing. There is no cure for TSC, therefore symptomatic therapy is the best possible choice, including mTOR inhibitors, vigabatrin and other antiepileptic drugs for the seizures, and neurosurgery in cases of life-threatening neurological symptoms. The aim of the study is established TSC specific biomarker/s. Such biomarkers aim to facilitate the diagnosis, treatment personalization and monitoring. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01687179 -
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
|
Phase 1 | |
| Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
| Completed |
NCT00552955 -
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
|
||
| Unknown status |
NCT00490789 -
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
|
Phase 2 | |
| Not yet recruiting |
NCT05087134 -
Characterizing LAM With 11C-Choline PET/CT
|
Early Phase 1 | |
| Completed |
NCT02009241 -
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
|
N/A | |
| Recruiting |
NCT05190627 -
Effect of Loratadine in Lymphangioleiomyomatosis
|
Phase 2 | |
| Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
| Completed |
NCT02859194 -
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
|
N/A | |
| Completed |
NCT01353209 -
Letrozole for Lymphangioleiomyomatosis
|
Phase 2 | |
| Completed |
NCT03253913 -
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
|
Phase 2 | |
| Recruiting |
NCT02432560 -
Safety and Durability of Sirolimus for Treatment of LAM
|
||
| Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Recruiting |
NCT04577937 -
Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis
|
N/A | |
| Completed |
NCT00005906 -
Treatment With Octreotide in Patients With Lymphangioleiomyomatosis
|
Phase 2 | |
| Recruiting |
NCT01799538 -
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
|
Phase 1/Phase 2 | |
| Completed |
NCT00989742 -
Doxycycline In Lymphangioleiomyomatosis (LAM)
|
Phase 4 | |
| Recruiting |
NCT06160310 -
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
|
||
| Enrolling by invitation |
NCT05727852 -
Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
|